Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21475414 | 0.86 | RECQL (0.41) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL21475309 | 0.79 | ICAM1 (0.44) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL21475315 | 0.79 | ICAM1 (0.44) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL23007994 | 0.79 | ICAM1 (0.44) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL21475373 | 0.75 | ICAM1 (0.48) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL21475296 | 0.74 | ICAM1 (0.41) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL21475336 | 0.74 | ICAM1 (0.41) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL23008236 | 0.74 | ICAM1 (0.41) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL21475312 | 0.74 | ICAM1 (0.41) | RECQLICAM1TAS2R46ATMCYP3A4 | |
| SCHEMBL21475294 | 0.74 | ICAM1 (0.41) | RECQLICAM1TAS2R46ATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047283-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| WO-2019198678-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | 高砂香料工業株式会社 | 2019-10-17 | — | — | WO | disclosed |
| US-20160190447-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047283-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | NR0B1, CBR1, DCXR | RECQL 4114/4885ICAM1 3353/4885TAS2R46 997/4885 |
| US-20160190447-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | L1CAM, EFNA1, EPCAM | RECQL 1926/4885ICAM1 256/4885TAS2R46 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.